Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 70
- Registration Number
- NCT05306418
- Locations
- 🇵🇹
Centro Hospitalar Lisboa Central - Hospital Dona Estefânia, Lisboa, Portugal
🇺🇸Univ Hosp Cleveland Med Ctr, Cleveland, Ohio, United States
🇮🇳Seth GS Medical College & KEM Hospital, Mumbai, Maharashtra, India
A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 19
- Registration Number
- NCT05262595
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 683
- Registration Number
- NCT05259033
- Locations
- 🇺🇸
Endeavor Health, Skokie, Illinois, United States
🇨🇳Zhu Xianyi Memorial Hospital of Tianjin Medical University-Endocrinology, Tianjin, Tianjin, China
🇺🇸Pri Med Grp dba/Gil Ctr Fam, Gilbert, Arizona, United States
A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity
- Conditions
- Overweight and Obesity
- Interventions
- Drug: NNC0174 0833
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05254158
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, Shanghai, China
Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific
- Conditions
- Obesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12404
- Registration Number
- NCT05250427
- Locations
- 🇻🇳
Novo Nordisk Investigational Site, Ho Chi Minh, Vietnam
Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy
- Conditions
- Postmenopausal Vaginal Atrophy
- Interventions
- Drug: Non-Vagifem® LDVE, Estradiol
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 500000
- Registration Number
- NCT05243823
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Soeborg, Denmark
A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT05236517
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
- Conditions
- Healthy Volunteers (Diabetes Mellitus, Type 2)
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT05232708
- Locations
- 🇬🇧
Parexel CPRU, Level 7, Harrow, Middlesex, United Kingdom
Awareness, Care & Treatment In Obesity Management - An Observation in Switzerland
- Conditions
- Obesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1152
- Registration Number
- NCT05232786
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®
- Conditions
- Adult Growth Hormone Deficiency
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT05230550
- Locations
- 🇯🇵
Gifu University Hospital, Gifu, Japan
🇯🇵Tsugaru General Hospital, Goshogawara-shi, Aomori-ken, Japan
🇯🇵Gunma University Hospital, Dept. of Endocrinology and Diabetes, Gunma, Japan